Eli Lilly and Incyte's JAK inhibitor Olumiant reduced the risk of death by 13% in hospitalised COVID-19 patients when added to other drugs, according to new results from the UK RECOVERY trial.
Eli Lilly has two positive trials of its JAK inhibitor Olumiant in skin disorder atopic dermatitis (AD), which could finally unlock the drug’s potential in the US. Top-line data from the two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback